Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07046975 · ClinicalTrials.gov registry record · Phase 3
Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone
A Phase 3 study, sponsored by Sarfez Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT07046975: Completed Phase 3 study, sponsored by Sarfez Pharmaceuticals.
NCT07046975 is a Phase 3 study that has completed, run by Sarfez Pharmaceuticals. The registered enrollment target is 24 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07046975, a Phase 3 study, has completed, sponsored by Sarfez Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.
Primary Outcome
Measurement of torsemide in the blood for Cmax.
Interventions
- DRUG Torsemide and Spironolactone tablet
- DRUG Torsemide Tablets and Spironolactone Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-06-15 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 3 |
What the finished NCT07046975 record still lists
NCT07046975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Torsemide and Spironolactone tablet is the first listed.
NCT07046975 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07046975 about?
NCT07046975 is a clinical study titled "Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone". To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.
What is the current status of trial NCT07046975?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2025-06-15. Estimated completion is 2026-02-28.
What interventions are being tested in trial NCT07046975?
The interventions under investigation include: Torsemide and Spironolactone tablet (DRUG), Torsemide Tablets and Spironolactone Tablets (DRUG).
Who is sponsoring clinical trial NCT07046975?
This trial is sponsored by Sarfez Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07046975's enrollment target sits among peer trials
24 1943rd of 2000 higher than 49 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI